MOLECULAR PROFILING IN LOW-GRADE EC 57 3 Pelvic 18 (41.9) 1 (100.0) 2 (40.0) 6 (46.2) 9 (37.5) Para aortic 7 (16.3) 0 (0.0) 0 (0.0) 4 (30.8) 3 (12.5) Pelvic and para aortic 6 (13.9) 0 (0.0) 2 (40.0) 0 (0.0) 4 (16.7) Unknown which nodes 12 (27.9) 0 (0.0) 1 (20.0) 3 (23.0) 8 (33.3) Nx 40 (10.2) 3 (9.1) 5 (6.4) 13 (18.1) 24 (11.4) FIGO stage Early (I-II) 290 (73.8) 27 (81.8) 68 (87.2) 37 (51.4) 158 (75.2) <.001 Advanced (III-IV) 103 (26.2) 6 (18.2) 10 (12.8) 35 (48.6) 52 (24.8) Adjuvant treatment None 97 (24.7) 6 (18.2) 15 (19.2) 17 (23.6) 59 (28.1) .02 Radiotherapy 225 (57.3) 20 (60.6) 56 (71.8) 34 (47.2) 115 (54.8) EBRT 67 (29.8) 8 (40.0) 15 (26.8) 16 (47.1) 28 (24.3) VBT 89 (39.6) 6 (30.0) 25 (44.6) 7 (20.6) 7 (20.6) ERBT+VBT 47 (20.9) 5 (25.0) 10 (17.9) 5 (14.7) 5 (14.7) Unknown 22 (9.8) 1 (5.0) 6 (10.7) 6 (17.6) 6 (17.6) Chemotherapy 33 (8.4) 2 (6.1) 2 (2.6) 13 (18.1) 16 (7.6) Chemoradiation 34 (8.7) 5 (15.2) 4 (5.1) 6 (8.3) 19 (9.0) Unknown 4 (1.0) 0 (0.0) 1 (1.3) 2 (2.8) 1 (0.5) Mortality Recurrence 74 (18.8) 1 (3.1) 12 (15.8) 30 (50.8) 31 (15.4) <.001 Mortality 90 (22.9) 2 (6.1) 8 (10.3) 38 (52.8) 42 (20.0) <.001 EC-related mortality 73 (18.6) 1 (3.0) 6 (7.7) 33 (45.8) 33 (15.7) <.001 Data is presented as No. (%), median (IQR) Abbreviations: POLE, Polymerase epsilon; MSI, Microsatellite instability; TP53, Tumor protein 53; NSMP, No-specific molecular profile; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial cancer; MI, myometrial invasion; LVSI, lymphovascular space invasion; N0, negative lymph nodes, N1, positive lymph nodes; Nx, no information about the lymph nodes; FIGO, Federation International of Gynecology and Obstetrics; EBRT, external beam radition therapy; VBT, vaginal brachytherapy; EC, endometrial cancer. Table 1. Continued
RkJQdWJsaXNoZXIy MTk4NDMw